查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1917791

自動化和封閉式細胞治療市場－2026-2031年預測

Automated and Closed Cell Therapy Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計自動化和封閉式細胞療法市場將從 2025 年的 17.68 億美元成長到 2031 年的 42.36 億美元，複合年成長率為 15.68%。

自動化和封閉式細胞療法市場正透過將自動化技術融入封閉式流程而不斷發展，從而提升擴充性、安全性和一致性。再生醫學在醫療保健領域的日益普及也推動了市場擴張。自動化平台能夠精準、大量生產，提高癌症免疫療法（例如CAR-T療法）的療效。為了降低成本、減少空間佔用和人工干預，人們正在大力投資緊湊型自動化系統。

自動化封閉式細胞治療系統將封閉式生產環境與機器人和軟體驅動的細胞分離、擴增、收穫、配製和填充流程結合。這些系統最大限度地降低了污染風險，實現了產品標準化，並支持個人化療法的規模化生產。隨著腫瘤學、自體免疫疾病和再生醫學等領域適應症的不斷拓展，對可重複、高品質細胞產品的需求日益成長，該市場正經歷穩定成長。

關鍵成長要素包括自動化帶來的多方面優勢，例如：流程標準化以實現統一的處理；受控環境下更高的產量帶來的可擴展擴充性；封閉迴路境下更低的污染；以及因減少人事費用和錯誤率而帶來的成本效益。利用人體自身修復機制的再生醫學日益普及，推動了對可靠的自動化生產的需求，以提供有效的細胞產品。隨著癌症發生率的不斷上升，CAR-T療法等先進免疫療法至關重要，而自動化封閉系統能夠實現大規模、一致的、特定患者的治療。

阻礙因素包括基礎設施不足，例如許多設施無塵室使用受限以及缺乏熟練相關人員，這些都會延緩技術的普及。此外，諸如維持產品品質、在不同自動化平台間實現通訊協定標準化以及消除人們對人工監管減少的擔憂等挑戰，也會影響利害關係人的接受度。

從地區來看，由於技術領先、數位醫療的整合、癌症發病率上升、醫護人員和患者的意識以及關鍵創新者的集中等因素，預計北美將佔據相當大的佔有率。

主要企業包括 Lonza，該公司提供 Cocoon®，這是一個具有整合工作流程的自動化封閉式細胞療法生產平台；以及 Miltenyi Biotec，該公司提供 MACS，這是一種細胞分離和富集技術，是研究和臨床流程中自動化處理的基礎。

總體而言，市場正在經歷強勁成長，並有望透過封閉式自動化克服細胞療法的擴充性障礙，從而在快速發展的再生醫學領域中解決污染、一致性和成本方面的挑戰，使更多人能夠獲得變革性療法。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在快速變化的環境中做出策略決策，並發現新的商機和收入來源。
  • 受眾廣泛：對Start-Ups、研究機構、顧問公司、中小企業和大型企業都很有用且經濟實惠。

公司如何使用我們的報告範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

研究範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

第5章 自動化/封閉式細胞療法市場：依治療方法分類

  • 介紹
  • 幹細胞療法
  • 非幹細胞療法

第6章 自動化/封閉式細胞療法市場：依規模分類

  • 介紹
  • 商業化前/研發規模
  • 商業規模

第7章 按最終使用者分類的自動化和封閉式細胞治療市場

  • 介紹
  • 製藥和生物技術公司
  • 研究和學術機構
  • 其他

第8章：按地區分類的自動化和封閉式細胞治療市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Miltenyi Biotec
  • Lonza
  • Fresenius Kabi
  • Danaher Corporation
  • BioSpherix, LLC
  • Terumo Corporation
  • Sartorius AG
  • ThermoGenesis
  • Cellares Inc.
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615765

Automated And Closed Cell Therapy Market is expected to grow at a 15.68% CAGR, increasing to USD 4.236 billion in 2031 from USD 1.768 billion in 2025.

The automated and closed cell therapy market is advancing through integration of automation in closed-system processes, enhancing scalability, safety, and consistency. Rising adoption of regenerative medicine across healthcare sectors is accelerating market expansion. Automated platforms are improving treatment efficacy in cancer immunotherapies such as CAR-T by enabling precise, high-volume production. Significant investments are flowing into compact, automated systems to lower costs, space requirements, and manual intervention.

Automated and closed cell therapy combines closed manufacturing environments with robotic or software-driven processes for cell isolation, expansion, harvesting, formulation, and fill-finish. These systems minimize contamination risks, standardize outputs, and support scalable production of personalized therapies. The market is growing steadily, driven by demand for reproducible, high-quality cellular products amid expanding indications in oncology, autoimmune diseases, and regenerative applications.

Key growth drivers include the multifaceted benefits of automation, such as process standardization for uniform therapies, enhanced scalability through higher yields in controlled settings, reduced contamination in closed environments, and cost efficiencies via lowered labor and error rates. Increasing popularity of regenerative medicine, focused on harnessing innate repair mechanisms, amplifies needs for reliable, automated manufacturing to deliver viable cell products. Growing cancer prevalence necessitates advanced immunotherapies like CAR-T, where automated closed systems ensure consistent, patient-specific engineering at scale.

Restraints encompass infrastructure gaps, including limited cleanroom access and skilled personnel at many facilities, potentially slowing adoption. Challenges in maintaining product quality, standardizing protocols across automated platforms, and addressing perceptions of reduced human oversight may influence stakeholder acceptance.

Geographically, North America is expected to hold significant share, supported by technological leadership, digital healthcare integration, elevated cancer incidence, provider/patient awareness, and concentration of key innovators.

Leading companies include Lonza, offering the Cocoon(R) platform for automated, closed cell therapy manufacturing with integrated workflows. Miltenyi Biotec provides MACS technology for cell isolation and enrichment, foundational to automated processing in research and clinical pipelines.

Overall, the market is progressing robustly, positioned to overcome scalability barriers in cell therapy through closed automation, enabling broader access to transformative treatments while addressing contamination, consistency, and cost challenges in a rapidly evolving regenerative landscape.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Automated and Closed Cell Therapy Market Segmentation

  • By Therapy Type
  • Stem-Cell Therapy
  • Non-Stem-Cell Therapy
  • By Scale
  • Pre-Commercial / R&D Scale
  • Commercial Scale
  • By End-User
  • Pharmaceuticals & Bio-Tech Companies
  • Research & Academic Institute
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AUTOMATED AND CLOSED SELL THERAPY MARKET BY THERAPY TYPE

  • 5.1. Introduction
  • 5.2. Stem-Cell Therapy
  • 5.3. Non-Stem-Cell Therapy

6. AUTOMATED AND CLOSED SELL THERAPY MARKET BY SCALE

  • 6.1. Introduction
  • 6.2. Pre-Commercial / R&D Scale
  • 6.3. Commercial Scale

7. AUTOMATED AND CLOSED SELL THERAPY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceuticals & Bio-Tech Companies
  • 7.3. Research & Academic Institute
  • 7.4. Others

8. AUTOMATED AND CLOSED SELL THERAPY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Miltenyi Biotec
  • 10.2. Lonza
  • 10.3. Fresenius Kabi
  • 10.4. Danaher Corporation
  • 10.5. BioSpherix, LLC
  • 10.6. Terumo Corporation
  • 10.7. Sartorius AG
  • 10.8. ThermoGenesis
  • 10.9. Cellares Inc.
  • 10.10. Thermo Fisher Scientific, Inc.
  • 10.11. Merck KgaA

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations